The FDA yesterday approved Pfizer’s Eraxis, an antifungal for the treatment of the bloodstream infection candidemia.
Candidemia is the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximately 40 percent. In the United States, candidemia affects approximately one in 5,000 people, resulting in an estimated 60,000 cases each year.
Pfizer said in published reports that the drug will be available as a hospital -based treatment and is delivered intravenously for about 14 days. Analysts predict sales of Eraxis will reach $350 million a year by 2010.
Eraxis was developed by Vicuron Pharmaceuticals, which Pfizer acquired last September. Another drug from that purchase, the antibiotic dalbavancin, is awaiting FDA approval.